Buy at this blue line for a shot at trading profitably
There are so many indicators out there on when to buy and sell. Nic uses none. He looks at a chart and buys when a stock “pushes” off this blue line. What blue line? Find out on the next page. It’ll change how you make money from stocks. Click here for the details.
- AstraZeneca Plc (NASDAQ:AZN) has paused an active Phase 1 trial of AZD5991, a direct inhibitor of MCL-1, citing a potential safety issue.
- Two years ago, the FDA hit Amgen Inc (NASDAQ:AMGN) with a clinical hold on its MCL-1 inhibitor AMG 397 following signs of cardiac toxicity.
- AstraZeneca's AZD5991 belongs to the same class therapy.
- The trial suspension, noted on ClinicalTrials.gov, came on October 19: "The study has been put on hold to allow further evaluation of safety-related information," the update said.
- AstraZeneca planned to recruit 144 patients for the study, slated to complete in March 2023.
- The trial was assessing AZD5991, either alone or combined with AbbVie Inc (NYSE:ABBV) / Roche Holding AG's (OTC:RHHBY) Venetoclax in relapsed or refractory acute myeloid leukemia (AML).
- The drug works by targeting apoptosis, the process of programmed cell death, specifically in blood cancer.
- Price Action: AZN shares are up 0.71% at $60.6 during the market session on the last check Wednesday.
Buy at this blue line for a shot at trading profitably
There are so many indicators out there on when to buy and sell. Nic uses none. He looks at a chart and buys when a stock “pushes” off this blue line. What blue line? Find out on the next page. It’ll change how you make money from stocks. Click here for the details.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!